Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy.
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy.
复制标题
在免疫检查点抑制剂诱导的大疱性类天疱疮中靶向白细胞介素 (IL)-4/IL-13：关于 T 辅助细胞 2 免疫在黑色素瘤和免疫治疗中的有益作用的警告。
DOI：
10.1093/bjd/ljad324
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Amber,KyleT
中科院分区：
文献类型：
--
作者：
Guerrero-Juarez,ChristianF;Goyal,ParulK;Amber,KyleT
DUPILUMA已被建议用于治疗免疫检查点抑制剂(ICI)诱导的大疱性类天疱疮。在这封信中，我们对针对Th2途径的靶向抑制表示谨慎，因为目前的证据表明，Th2反应，特别是嗜酸性粒细胞增多，对ICI反应，特别是在黑色素瘤中的有益影响。
The use of dupilumab has been suggested in the treatment of immune checkpoint inhibitor (ICI)-induced bullous pemphigoid. In this letter, we express caution with the targeted inhibition of the Th2 pathway given current evidence suggesting the beneficial effect of the Th2 response, particularly eosinophilia, to ICI responses, particularly in melanoma.